SPECIALTY GUIDELINE MANAGEMENT

NPLATE (romiplostim)

POLICY

I. INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

FDA-Approved Indication
Treatment of thrombocytopenia in patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy

All other indications are considered experimental/investigational and are not a covered benefit.

II. CRITERIA FOR INITIAL APPROVAL

Chronic or persistent primary immune thrombocytopenia (ITP)
Authorization of 6 months may be granted to members with chronic or persistent ITP who meet all of the following criteria:

A. Inadequate response or intolerance to prior therapy with corticosteroids, immunoglobulins, or splenectomy
B. Untransfused platelet count at time of diagnosis is less than 30x10^9/L OR 30x10^9/L to 50x10^9/L with symptomatic bleeding (e.g., significant mucous membrane bleeding, gastrointestinal bleeding or trauma) or risk factors for bleeding (see Section IV).

III. CONTINUATION OF THERAPY

Chronic or persistent ITP
A. Authorization of 12 months may be granted to members with current platelet count less than or equal to 200x10^9/L.
B. Authorization of 12 months may be granted to members with current platelet count greater than 200 x10^9/L for whom Nplate dosing will be adjusted to achieve a platelet count sufficient to avoid clinically important bleeding.

IV. APPENDIX

Examples of risk factors for bleeding (not all inclusive)
- Undergoing a medical or dental procedure where blood loss is anticipated
- Comorbidity (e.g., peptic ulcer disease, hypertension)
- Mandated anticoagulation therapy
• Profession (e.g., construction worker) or lifestyle (e.g., plays contact sports) that predisposes patient to trauma

V. REFERENCES
2. CVS Caremark Clinical Programs Review. Focus on Immune Thrombocytopenia (ITP) Programs; October 2010.